title: Deceased donor kidney transplantation in autosomal dominant polycystic kidney disease: a single-center experience.
abstract: Renal transplantation (RTx) has become the treatment of choice for end-stage renal disease (ESRD) in autosomal dominant polycystic kidney disease (ADPKD), the most common genetic kidney disease. Because of the inheritable nature of this disease, live related donors might be avoided due to the fear of future appearance of polycystic disease. This retrospective singlecenter study was undertaken to evaluate patient/graft survival function vis-a-vis serum creatinine (SCr), rejection episodes and mortality in ADPKD vs matched control patients. Between 2000 and 2009, 18 (7.4%) deceased donor renal transplant (DDRTx) were performed for ESRD due to ADPKD. Diagnosis of ADPKD was established by family history and ultrasound. An individualized approach was applied for the need of pre-transplant nephrectomy. All recipients received rabbit-anti-thymocyte globulin induction and maintenance triple immunosuppression. Delayed graft function was observed in 33% patients, and 16% had biopsy-proven acute rejection. Over mean follow-up of 4.67 ± 2.2 years, patient and graft survival rates were 72.22% and 83.33%, with mean SCr (mg/dL) of 1.44 ± 0.54, 1.78 ± 0.42 and 2.2 ± 0.6 at 1, 5 and 10 years. Overall, 44.4% (n-8) underwent pre-transplant nephrectomy. Infection and cardio/cerebrovascular events were the main causes of death. Patient, graft survival and acute rejection were similar between ADPKD and control group. DDRTx in ADPKD has acceptable patient and graft survival. Because of the inheritable nature of the disease, and unavailability of genetic linkage analysis as a routine, DDRTx is a viable option to avoid using unrelated donors.
authors.affiliation: Department of Nephrology and Transplantation Medicine, Institute of Transplantation Sciences - Institute of Kidney Diseases and Research Centre, Ahmedabad, India. drvivekkute@rediffmail.com
authors.forename: Vivek B
authors.initials: VB
authors.lastname: Kute
authors.forename: Pankaj R
authors.initials: PR
authors.lastname: Shah
authors.forename: Kamal R
authors.initials: KR
authors.lastname: Goplani
authors.forename: Manoj R
authors.initials: MR
authors.lastname: Gumber
authors.forename: Aruna V
authors.initials: AV
authors.lastname: Vanikar
authors.forename: Himanshu V
authors.initials: HV
authors.lastname: Patel
authors.forename: Siddharth H
authors.initials: SH
authors.lastname: Jain
authors.forename: Divyesh P
authors.initials: DP
authors.lastname: Enginner
authors.forename: Hargovind L
authors.initials: HL
authors.lastname: Trivedi
mesh_terms: D000328:Adult; D003404:Creatinine / Q000097:blood; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D053208:Kaplan-Meier Estimate; D016030:Kidney Transplantation; D008875:Middle Aged; D016891:Polycystic Kidney, Autosomal Dominant / Q000401:mortality / Q000601:surgery*; D012189:Retrospective Studies
chemical_list: D007166:Immunosuppressive Agents; D003404:Creatinine